Results 61 to 70 of about 322,823 (355)

Motor and Somatosensory Evoked Potential Monitoring Without Wakeup Test during Scoliosis Surgery

Journal of Rawalpindi Medical College, 2019
Background: Available evidence suggests that Transcranial electric motor evoked potentials and somatosensory evoked potential are safe methods to check the integrity of the spinal cord during spine deformity correction surgery. We compare the efficacy of
Muhammad Kamran Ayoob, Ammar Dogar, Anum Hafeez, Abdullah Shah, Jamil Ahmed, Amer Aziz   +5 more
doaj  

Threshold variation of transcranial motor evoked potential with threshold criterion in frontotemporal craniotomy

Clinical Neurophysiology Practice, 2019
Objective: Motor threshold usually varies in the intraoperative motor evoked potential (MEP) by transcranial evoked stimulation (TES). This study investigated the degree of change in the motor threshold before and after surgery in TES-MEP monitoring with
Kohei Kanaya, Tetsuya Goto, Tetsuyoshi Horiuchi, Kazuhiro Hongo   +3 more
doaj   +1 more source

Sensitivity and specificity in transcranial motor-evoked potential monitoring during neurosurgical operations

Surgical neurology international, 2011
Background: Intraoperative transcranial motor-evoked potential (TCMEP) monitoring is widely performed during neurosurgical operations. Sensitivity and specificity in TCMEP during neurosurgical operations were examined according to the type of operation ...
Satoshi Tanaka, Takashi Tashiro, A. Gomi, J. Takanashi, H. Ujiié   +4 more
semanticscholar   +1 more source

Statistical Model of Motor-Evoked Potentials

IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2019
Motor-evoked potentials (MEPs) are widely used for biomarkers and dose individualization in transcranial stimulation. The large variability of MEPs requires sophisticated methods of analysis to extract information fast and correctly. Development and testing of such methods relies on the availability for realistic models of MEP generation, which are ...
Stefan M. Goetz, S. M. Mahdi Alavi, Zhi-De Deng, Angel V. Peterchev   +3 more
openaire   +3 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Safety of sugammadex muscle relaxation reversal during spinal surgery with motor evoked potential monitoring [PDF]

Jichu yixue yu linchuang
Objective To explore the effect of sugammadex on safety indicators such as body movement, choking, peak airway pressure during spinal surgery with motor evoked potential monitoring.
MA Bo, JIAN Minyu, JING Longnian, WANG Chengwei, LIU Haiyang, HAN Ruquan
doaj   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Limitation of Intraoperative Transcranial Electrical Stimulation-Motor Evoked Potential Monitoring During Brain Tumor Resection Adjacent to the Primary Motor Cortex [PDF]

Annals of Rehabilitation Medicine, 2018
Transcranial electrical stimulation-motor evoked potential (TES-MEP) is a valuable intraoperative monitoring technique during brain tumor surgery. However, TES can stimulate deep subcortical areas located far from the motor cortex.
Hui Jae Do, Han Gil Seo, Byung-Mo Oh, Chul-Kee Park, Jin Wook Kim, Young Doo Choi, Seung Hak Lee   +6 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

Molecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla, Jana R. Crespo, Saioa Garcia‐Longarte, Marta Fidalgo, Sara del Palacio, Natalia Martin‐Martin, Onintza Carlevaris, Ianire Astobiza, Sonia Fernández‐Ruiz, Marc Guiu, Laura Bárcena, Isabel Mendizabal, Ana M. Aransay, Mariona Graupera, Roger R. Gomis, Arkaitz Carracedo   +15 more
wiley   +1 more source